Bayer stock crumbles after $2B Roundup loss in California by Kyle Blankenship Tuesday, May 14, 2019 With angry investors and thousands of lawsuits bearing down, Bayer is scrambling to keep its head above water. Looks like relief isn’t coming soon.
Lilly scores targeted liver cancer win for Cyramza by Kyle Blankenship Monday, May 13, 2019 After Eli Lilly’s Cyramza flopped a liver cancer trial five years ago, the drugmaker’s chances in the field looked slim. That all changed Monday.
Bayer's older meds deliver a surprisingly good show by Angus Liu Thursday, April 25, 2019 China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.
Exelixis takes Cabometyx into crowded liver cancer field by Angus Liu Tuesday, January 15, 2019 Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.
Merck suits up for Opdivo battle with Keytruda liver cancer OK by Carly Helfand Monday, November 12, 2018 Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.
Big Pharmas slash cancer drug prices again for Chinese insurance by Angus Liu Wednesday, October 10, 2018 Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
Lilly, Chi-Med's China-made drug lands key cancer nod by Angus Liu Wednesday, September 5, 2018 China, which has been waving through cancer drugs made by multinational pharmas, can now count a homegrown one among its approvals.
Bayer takes giant colon on tour to spur colorectal cancer talk by Carly Helfand Thursday, May 10, 2018 Bayer is taking a giant colon on tour. Yes, you read that right.
Bayer's growth-driving quintet? Better make that a trio by Angus Liu Thursday, May 3, 2018 A strong euro doesn't explain away Bayer's consumer health stall—or the low turnout for key cancer meds Xofigo and Stivarga.
8. Bayer by Carly Helfand Bayer’s 2017 sales may have grown by 1.5% over 2016, but not even the company’s CEO, Werner Baumann, would call it a good year.
